PALVELLA THERAPEUTICS, INC. - PVLA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | First Light Asset Management, LLC | 7.49% | 887,031 | View |
| Feb 17, 2026 | SCHEDULE 13G | Mathew P. Arens | 7.49% | 887,031 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 3.8% | 471,202 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 3.8% | 471,202 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.8% | 341,883 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 2.8% | 341,883 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.4% | 53,187 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.4% | 53,187 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 6.6% | 813,085 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 7.1% | 879,009 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 7.1% | 879,009 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 7.1% | 879,009 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences Public Fund, L.P. | 6.0% | 706,360 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLSP, L.P. | 6.0% | 706,360 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLSP, L.L.C. | 6.0% | 706,360 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences X, L.P. | 0.0% | 4,730 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS X, L.P. | 0.0% | 4,730 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS X, L.L.C. | 0.0% | 4,730 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences XI, L.P. | 0.1% | 7,517 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XI, L.P. | 0.1% | 7,517 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XI, L.L.C. | 0.1% | 7,517 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences XII, L.P. | 0.0% | 3,793 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XII, L.P. | 0.0% | 3,793 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XII, L.L.C. | 0.0% | 3,793 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | James N. Topper | 0.0% | 4,730 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Patrick J. Heron | 0.0% | 4,730 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.4% | 634,307 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF I GP LLC | 5.4% | 634,307 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 4.0% | 474,740 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF II GP LLC | 4.0% | 474,740 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.5% | 54,840 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.5% | 54,840 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.4% | 1,109,047 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 1,181,194 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 1,181,194 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 1,181,194 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | SUVRETTA CAPITAL MANAGEMENT, LLC | 7.4% | 822,400 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | AVERILL MASTER FUND, LTD. | 6.5% | 714,463 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | AARON COWEN | 7.4% | 822,400 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.